Geron Corp : GERN Details Finding the best opportunities to buy and sell stocks daily.

Symbol:

GERN

Sector:

Healthcare

Current Price

$1.40

RSI

39.022

Beta:

1.61869

Description:

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. It holds rights to imetelstat, a telomerase inhibitor in Phase 2/3 clinical trials, which inhibits the uncontrolled proliferation of malignant progenitor cells in hematologic myeloid malignancies to reduce dysfunctional blood cell production and enable recovery of normal blood cell production. The company was founded in 1990 and is headquartered in Menlo Park, California.

November 05, 2020
-17.557 %
8.092 %
-28.676 %
-37.390 %
29.7M
-15.5M

$460,000
$1,066,000
$1,065,000
$6,162,000
$36,371,000
-131.739 %
0.094 %
-478.592 %
-490.247 %

$-68,353,000
$-27,017,000
$-27,916,000
$-29,537,000
$46,000
-60.474 %
3.328 %
5.807 %
-100.156 %

News

Press Releases

Notable Dates

All stock recommendations and comments are all opinions. Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal ownership, may influence or factor into a stock analysis or opinion. All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action.